Hammarlund-Udenaes Margareta, Fridén Markus, Syvänen Stina, Gupta Anubha
Division of Pharmacokinetics and Drug Therapy, Department of Pharmaceutical Biosciences, Uppsala University, P.O. Box 591, 751 24 Uppsala, Sweden.
Pharm Res. 2008 Aug;25(8):1737-50. doi: 10.1007/s11095-007-9502-2. Epub 2007 Dec 5.
To define and differentiate relevant aspects of blood-brain barrier transport and distribution in order to aid research methodology in brain drug delivery. Pharmacokinetic parameters relative to the rate and extent of brain drug delivery are described and illustrated with relevant data, with special emphasis on the unbound, pharmacologically active drug molecule. Drug delivery to the brain can be comprehensively described using three parameters: Kp,uu (concentration ratio of unbound drug in brain to blood), CLin (permeability clearance into the brain), and Vu,brain (intra-brain distribution). The permeability of the blood-brain barrier is less relevant to drug action within the CNS than the extent of drug delivery, as most drugs are administered on a continuous (repeated) basis. Kp,uu can differ between CNS-active drugs by a factor of up to 150-fold. This range is much smaller than that for log BB ratios (Kp), which can differ by up to at least 2,000-fold, or for BBB permeabilities, which span an even larger range (up to at least 20,000-fold difference). Methods that measure the three parameters Kp,uu, CLin, and Vu,brain can give clinically valuable estimates of brain drug delivery in early drug discovery programmes.
定义并区分血脑屏障转运和分布的相关方面,以辅助脑内药物递送的研究方法。描述并举例说明与脑内药物递送速率和程度相关的药代动力学参数,特别强调游离的、具有药理活性的药物分子。可使用三个参数全面描述药物向脑内的递送:Kp,uu(脑内与血液中游离药物的浓度比)、CLin(进入脑内的通透清除率)和Vu,brain(脑内分布)。由于大多数药物是持续(重复)给药,血脑屏障的通透性与药物在中枢神经系统内的作用相比,药物递送程度的相关性更小。中枢神经系统活性药物之间的Kp,uu差异可达150倍。该范围远小于log BB比值(Kp)的差异范围,后者差异可达至少2000倍,也小于血脑屏障通透性的差异范围(差异可达至少20000倍)。在早期药物发现计划中,测量Kp,uu、CLin和Vu,brain这三个参数的方法可为脑内药物递送提供具有临床价值的估计。